-+ 0.00%
-+ 0.00%
-+ 0.00%
Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2
Share
Listen to the news

Full-year 2026 guidance reaffirmed o Net sales expected to grow low single-digit and core operating income expected to decline low single-digit

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending